Table: Santen Pharm -9-MTH group results (IFRS)
10/02/2022 03:00
Feb 10 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2021 Dec 31, 2020 Mar 31, 2022
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 195.80 181.79 260.00
(+7.7 pct) (-0.3 pct) (+4.2 pct)
Operating 26.38 26.91 41.50
(-2.0 pct) (-7.0 pct) (+240.5 pct)
Pretax 25.67 26.60 41.00
(-3.5 pct) (-8.2 pct) (+250.8 pct)
Net 19.35 21.00
(-7.9 pct) (+3.4 pct)
EPS Basic 48.39 yen 52.56 yen 77.07 yen
EPS Diluted 48.32 yen 52.44 yen
Ann Div 28.00 yen 32.00 yen
-Q2 Div 16.00 yen 14.00 yen
-Q4 Div 14.00 yen 16.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T